On July 15, Merck rose 3.49% in pre-market trading, trading at $125.0/share, with turnover of $62.48 million.

On the news front, Merck announced that its Phase 3 trial of Keytruda (pembrolizumab) met the primary endpoint of progression-free survival in patients with mismatch repair-deficient advanced or recurrent endometrial cancer. The study demonstrated a statistically significant improvement in progression-free survival compared with platinum doublet chemotherapy in previously untreated patients. An interim analysis also showed a trend toward improved overall survival, though the data were not yet mature. The safety profile remained consistent with prior studies, with no new safety signals identified.

This data further expands Keytruda's indication footprint in precision oncology. Recent positive developments including FDA approval of Keytruda plus Padcev for muscle-invasive bladder cancer and Keytruda plus Trodelvy for first-line triple-negative breast cancer, combined with multiple investment banks raising price targets — JPMorgan to $140, BMO to $142, Wells Fargo to $150, and Scotiabank to $155 — have collectively bolstered market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)